Eli Lilly and Company (LLY) and Boehringer Ingelheim will collaborate on the Phase Ib trial to evaluate the combination of abemaciclib (LY2835219) and BI 836845 to treat metastatic breast cancer.

Lilly's abemaciclib (LY2835219) is an investigational, orally-administered product that inhibits cyclin-dependent kinases CDK 4 and CDK 6, thereby preventing the growth of cancer cells.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Boehringer's BI 836845 is an antibody that neutralises insulin-like growth factor (IGF)-1 / IGF-2 ligand.

Lilly oncology product development and medical affairs senior vice-president Richard Gaynor said: "We are pleased to join with Boehringer Ingelheim to study the potential of their molecule in combination with Lilly's abemaciclib, for which we have an active Phase III development programme underway.

"For patients living with metastatic breast cancer, the limited treatment options available make this an important area of focus for our efforts to advance the most innovative treatments."

"For patients living with metastatic breast cancer, the limited treatment options available make this an important area of focus for our efforts to advance the most innovative treatments."

While abemaciclib blocks CDK 4 and CDK 6 from triggering the growth of cancerous cells, BI 836845 binds to both IGF-1 and IGF-2, subsequently blocking activation of the respective receptor and resulting in decreased growth-promoting signalling, which may inhibit tumour growth.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The combination of abemaciclib and BI 836845 is expected to offer a complete pathway interference and inhibit growth of the cancerous cell cycle.

Subject to the Phase Ib trial results, the companies are intending to initiate Phase II trials of the combination for patients with HR+, HER2- metastatic breast cancer (mBC) and other solid tumours.